Quinolone-resistant Escherichia coli

Brazilian Journal of Infectious Diseases

Volumn 12, Issue 1, 2008, Pages 5-9

  Ito, Carmen Antonia Sanches ^a,c   Gales, Ana Cristina ^b   Tognim, Maria Cristina B ^b   Munerato, Patrícia ^b   Dalla Costa, Libera Maria ^c  

^a STATE UNIVERSITY OF PONTA GROSSA   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

Escherichia coli; Quinolone resistance; Urinary infection

Indexed keywords

ANTIINFECTIVE AGENT; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; GATIFLOXACIN; NALIDIXIC ACID; NORFLOXACIN; PROTEIN PARC; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

AGAR DILUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL MUTATION; BACTERIUM ISOLATION; CONTROLLED STUDY; DEVELOPED COUNTRY; DISK DIFFUSION; ESCHERICHIA COLI; GENE MUTATION; GENE SEQUENCE; NONHUMAN; PREDICTION; SENSITIVITY AND SPECIFICITY; URINALYSIS;

EID: 48249155048     PISSN: 14138670     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1413-86702008000100003     Document Type: Article

References (20)

1. Acar J.F., Goldstein F.W. Trends in: bacterial resistance to fluoroquinolones. Clin Infec Dis 1997;24:S67-73.
2. Andriole V.T. The quinolones: Academic Press, New York, 1998.
3. Berdichevski R.H., Zanardo J.C., Soilbelman M., Antonello I. Prevalência de uropatógenos e sua resistência aos antimicrobianos em uroculturas realizadas no Hospital São Lucas da PUCRS. Associação Médica do Rio Grande do Sul 1998;42:137-42.
4. Clinical Laboratory Standards Institute CLSI. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved Standard - Sixth Edition, M7-A6. CLSI, Wayne, Pensylvania, USA, 2003.
5. Clinical Laboratory Standards Institute CLSI. Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard - Eighth Edition. M2-A8. CLSI, Wayne, Pensylvania, USA, 2003.
6. Drlica K., Zhao X. DNA gyrase, topoisomerase IV and the 4 quinolones. Microbiol Mol Biol Rev 1997;61:377-92.
7. Drlica K. Mechanism of fluoroquinolone action. Curr Opin Microbiol 1999;2:504-8.
8. Drlica K. A strategy for fighting antibiotic resistance. ASM News 2001;67: 27-33.
9. Ena J., López-Perezagua M.M., Martínez-Peinado C., Cia-Barrio M.A., Ruíz-López I. Emergence of ciprofloxacin resistance in Escherichia coli isolates after widespread use of fluoroquinolones. Diagn Microbiol Infect Dis 1998;30:103-7.
10. Everett M., Jin Y.F., Ricci V., Piddock L.J.V. Contributions of individual mechanisms to fluoroquinolone resistance in 36 Escherichia coli strains isolated from humans and animals. Antimicrob Agents Chemother 1996;40:2380-6.
11. Gales A.C., Gordon K.A., Wilke W.W., Pfaller M.A., Jones R.N. Occurrence of single-point IA mutations among ciprofloxacinsusceptible Escherichia coli. Diagn Microbiol Infect Dis 2000a; 36:61-4.
12. Gales A.C., Jones R.N., Gordon K.A., et al. Activity and spectrum of 22 antimicrobial agents tested against urinary tract infection pathogens in hospitalized patients in Latin America: report from the second year of the SENTRY Antimicrobial Surveillance Program (1998). J Antimicrob Chemother 2000b;45:1295-303.
13. Georgiou M., Muñoz R., Román F., et al. Ciprofloxacin-resistant Haemophilus influenzae strains possess mutations in analogous positions of GyrA and ParC. Antimicrob Agents Chemother 1996;40:1741-4.
14. Heisig P. Genetic evidence for a role of ParC mutations in development of high-level fluoroquinolone resistance in Escherichia coli. Antimicrob Agents Chemother 1996;40:879-85.
15. Hooper D.C. Bacterial topoisomerases, anti-topoisomerases and anti-topoisomerase resistance. Clin Infect Dis 1998;27:54-63.
16. Hooper D.C. Emerging mechanisms of fluoroquinolone resistance. Emerg Infect Dis 2001;7:337-41.
17. Kern W.V., Steib-Bauert M., de With K., et al. Fluoroquinolone consumption and resistance in hematology-oncology patients: ecological analysis in two university hospitals 1999-2002. J Antimicrob Chemother 2005;55:57-60.
18. Lopes A.A., Salgado K., Martinelli R., Rocha H. Increase in the frequency of norfloxacin and ciprofloxacin resistance of bacteria isolated from urine culture. Revista da Associação Médica do Brasil 1998;44:196-200.
19. Sanders C.C. Mechanisms responsible for cross-resistance and dichotomous resistance among the quinolones. Clin Infect Dis 2001;32:S1-S8.
20. Vila J., Ruiz J., Marco F., et al. Association between double mutation in GyrA gene of ciprofloxacin-resistant clinical isolates of E. coli and MICs. Antimicrob Agents Chemother 1994;38:2477-79.